🇪🇺 Comparator: ProQuad™ (V221) in European Union

EMA authorised Comparator: ProQuad™ (V221) on 5 April 2006

Marketing authorisation

EMA — authorised 5 April 2006

  • Application: EMEA/H/C/000622
  • Marketing authorisation holder: Merck Sharp & Dohme B.V.
  • Local brand name: ProQuad
  • Indication: ProQuad is indicated for simultaneous vaccination against measles, mumps, rubella and varicella in individuals from 12 months of age. ProQuad can be administered to individuals from 9 months of age under special circumstances (e.g., to conform with national vaccination schedules, outbreak situations, or travel to a region with high prevalence of measles.
  • Status: approved

Read official source →

Other Immunology / Infectious Disease approved in European Union

Frequently asked questions

Is Comparator: ProQuad™ (V221) approved in European Union?

Yes. EMA authorised it on 5 April 2006.

Who is the marketing authorisation holder for Comparator: ProQuad™ (V221) in European Union?

Merck Sharp & Dohme B.V. holds the EU marketing authorisation.